Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19223769 | 0.71 | SPHK2 (0.67) | SPHK2SPHK1OPRD1S1PR1S1PR3 | |
| SCHEMBL12947562 | 0.71 | — | — | |
| SCHEMBL12947620 | 0.71 | — | — | |
| SCHEMBL20330675 | 0.69 | SPHK2 (0.64) | SPHK2SPHK1OPRD1S1PR1S1PR3 | |
| SCHEMBL4383140 | 0.69 | SPHK2 (0.64) | SPHK2SPHK1OPRD1S1PR1S1PR3 | |
| SCHEMBL16925054 | 0.69 | — | — | |
| SCHEMBL20781724 | 0.68 | SPHK2 (0.45) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL3476977 | 0.67 | GNAI3 (0.44) | GNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL8428941 | 0.67 | GNAI3 (0.44) | GNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL8424535 | 0.67 | GNAI3 (0.44) | GNAI3GNAO1GNAI1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250138-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2009018332-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250138-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | SLC40A1, SLCO1B1, SLCO2A1 | SPHK2 2784/4885SPHK1 2447/4885GNAI3 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.